Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special Meeting of Shareholders held June 18, 2025 (the “Meeting”).

Satellos is pleased to announce that all the nominees listed in the management information circular dated May 12, 2025 (the “Circular”), were elected as directors. Each director was elected with greater than 97% of the votes cast by shareholders present at the Meeting or represented by proxy with a total of 41.15% of the issued and outstanding common shares of the Company represented in person and by proxy at the Meeting.

The results of the vote are detailed below:

Director	Votes For	% For	Votes Against	% Against
Frank Gleeson	56,671,162	99.99	5,404	0.01
Franklin M. Berger	55,208,162	97.41	1,468,404	2.59
Brian Bloom	56,655,657	99.96	20,909	0.04
Stephanie Brown	56,672,157	99.99	4,409	0.01
Selwyn Ho	56,589,648	99.85	86,919	0.15
Iris Loew-Friedrich	56,589,657	99.85	86,909	0.15
Geoff Mackay	56,595,662	99.86	80,904	0.14
Adam Mostafa